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Abstract
Stigma and perceived social support can influence the decision to disclose HIV positive status, 
especially for people who inject drugs (PWID). In this analysis, the association between social 
support and HIV disclosure among 336 newly diagnosed HIV-infected PWID in Northern 
Vietnam was assessed. One month after diagnosis, 34.8% of participants had not disclosed to 
anyone. Disclosure to anyone and to a family member specifically, was associated with baseline 
social support in the form of positive interactions and a history of incarceration. Disclosing to a 
family member was less likely among those who had unprotected sex in the previous 3 months. 
Disclosure to an injecting partner was more likely among those with a history of being in a drug 
treatment program, knowing someone on ART and believing that ART is safe. These data suggest 
that social support may facilitate disclosure among family members, including spouses, while 
disclosure to injecting partners is greater when PWID know that ART is a safe and viable option.
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Self-disclosure of HIV positive serostatus is associated with earlier initiation of 
antiretroviral treatment (ART) [1], greater adherence to ART [2,3], safer sex practices [4], 
decreased anxiety, and greater social support [5–8]. In low-resource settings, disclosure has 
been shown to increase access to HIV care [1] as family members and friends may provide 
information about available services, facilitate transportation, and help to navigate 
paperwork and HIV services [9–11]. At the same time, disclosure may expose people living 
with HIV/AIDS (PLWHA) to stigma, discrimination, abandonment, and violence [12–15]. 
Informed counseling to encourage and facilitate disclosure, when appropriate, has important 
implications for preventing new HIV infections and for the treatment, care and support of 
people living with HIV/AIDS [16].
The decision-making process around disclosure has been conceptualized in the context of 
consequence theory [17] where the decision to disclose is a process of weighing costs and 
benefits. According to consequence theory, before making a decision to disclose one’s HIV 
status, a person must feel that the benefits will outweigh the risks and perceive that social 
support will be available as a result of disclosure [17]. In a meta-analysis of self-disclosure, 
concerns about stigma were negatively associated with disclosure while social support was 
positively associated with disclosure [18]. People who inject drugs (PWID), who are already 
marginalized in many societies, may be especially reluctant to disclose their HIV status 
given the potential for dual drug use and HIV-related stigma [14,15]. In cultures such as 
Vietnam’s, worry about self-stigma can be compounded by a concern that family members 
will also be stigmatized [19]. At the same time, the consequence model suggests that fear of 
stigma may be overcome by the need for emotional and instrumental support to manage the 
disease [5,17].
Among PWID in Vietnam, a group that has experienced a long history of institutional and 
cultural stigmatization and marginalization, fear of the additional stigma that HIV-positive 
status may bring from both family and community serves as a barrier to disclosure while the 
desire for comfort and support from family and other network members can support a 
decision to disclose [19,20]. In Vietnam, as in many other countries, the requirement to have 
an identified support person in order to enroll in ART, can provide an additional incentive 
for disclosure. Disclosure may also vary within an individual’s network. For example, 
PWID may disclose to a family member for social support, whereas they may disclose to an 
injecting partner to prevent further transmission to their partners, for social support or a 
combination of the two.
The objective of this investigation was to elucidate the association between perceived social 
support at the time of diagnosis and disclosure of HIV status (any disclosure, disclosure to a 
family member, and disclosure to an injecting partner) within 1 month of receiving a 
positive HIV test result among newly diagnosed PWID in Thai Nguyen province, Vietnam.
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Study design and population
We analyzed data from a baseline survey and a pre intervention survey conducted one 
month later in the Prevention with Positives Project, a four-arm randomized controlled trial 
evaluating the effectiveness of a multi-level intervention (community-structural and 
individual) to decrease stigma and HIV risk among HIV-infected PWID in Thai Nguyen 
Province, Vietnam [21]. Thai Nguyen is a semi-urban province with a population of 
approximately 50,000 that is located 100 miles northwest of Hanoi. The trial enrolled 455 
HIV-infected PWID who were recruited by outreach workers and peer referral. To be 
eligible for analysis, participants had to be newly diagnosed HIV-positive through testing in 
our study, be 18 years of age or older, and have injected drugs in the previous 6 months (n = 
336).
Data collection
In the baseline visit, participants were tested for HIV antibody (two simultaneously run 
rapid EIA tests) and administered a one-hour face-to-face interview using a structured 
questionnaire. The questionnaire included questions on demographics, drug use, sharing and 
disinfecting equipment, history of incarceration and drug treatment, HIV knowledge, 
number of sex partners and condom use. All potential participants received HIV counseling 
and testing at a project facility; post-test counseling encouraged disclosure, when 
appropriate, in accordance with the WHO/CDC protocol for HTC. HIV test results were 
provided one week after the baseline visit with HIV posttest counseling. A staff physician 
was consulted for other health problems that were identified, and active referrals for medical 
care were provided as needed. The research protocol, questionnaire and consent forms were 
reviewed and approved by the Thai Nguyen Center for Preventive Medicine IRB and the 
Johns Hopkins Bloomberg School of Public Health IRB. Participants returned 1 month later, 
and were administered a short survey, prior to the intervention, including questions on HIV 
disclosure and social support.
Outcome and risk factors
Self-disclosure was defined as responding “yes” to the question “Have you disclosed your 
HIV status to anyone” at the pre-intervention visit, 1 month after baseline. Disclosure to an 
injecting partner was defined as having disclosed to at least one injecting partner; disclosure 
to a family member was defined as having disclosed to a spouse, a parent, or other family 
members. These categories were not mutually exclusive since a participant may have 
disclosed to both an injecting partner and a family member.
We used a modified version of the MOS social support scale developed by Sherbourne et al 
[22] to assess 5 dimensions of support: emotional support (empathetic understanding), 
informational support (offering advice or information), tangible support (material or 
behavioral assistance), affectionate support (expressions of love) and positive social 
interaction (the availability to you of a person to do fun things). The MOS social support 
scale has been found to be reliable (all alphas > 0.91) and stable over time [22]. These 5 
dimensions of support were measured in 4 subscales: emotional/informational (EMI), 
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tangible (TAN), affectionate (AFF) and positive social interaction (POS). We used subscales 
as opposed to an overall support index given Sherbourne et al.’s demonstration of 
independence between these subscales and their supposition that the different types of 
support represented by each subscale may be “more beneficial for certain health outcomes” 
[23]. Furthermore, since the different subscales had different distributions and medians in 
our study, we looked at the 4 subscales separately in each analysis in order to understand 
how different types of social support may influence disclosure.
Other factors considered at the baseline visit included socio-demographics (e.g., age, marital 
status, education), injecting behaviors (e.g., needle/syringe sharing, sharing of other 
injecting equipment), sexual behaviors (e.g., unprotected sex), drug treatment and 
incarceration history, HIV knowledge which was assessed using a panel of seven true-false 
questions about HIV transmission, knowing someone that has taken ART, belief that ART is 
safe, health (e.g., self-reported health, CD4 count), and depression as measured using the 
Center for Epidemiologic Studies Depression Scale (CES-D) [24,25].
Statistical analysis
Frequency distributions and descriptive statistics were used to describe participants at 
baseline. Since the four social support subscales (EMI, TAN, AFF, POS) were not normally 
distributed, we categorized the variables into quartiles. Odds ratios for the association 
between disclosure and each social support subscale showed that the 1st and 2nd quartiles 
and the 3rd and 4th quartiles had similar proportions of disclosure. Therefore, we 
dichotomized each subscale at the median for the reported analyses. The number and 
proportion of people to whom each participant disclosed were calculated. A logit 
transformation was used to determine the probability and 95% confidence intervals of 1) 
disclosing to at least one person, 2) disclosure to a family member and 3) disclosure to an 
injecting partner. Bivariate analyses were conducted to assess associations between social 
support and disclosure and other participant characteristics and disclosure. Odds ratios and 
95% confidence intervals were calculated to determine the magnitude and direction of each 
relationship.
Variables marginally associated (p < .20 in bivariate analysis) with the disclosure types were 
modeled with multiple logistic regression to identify characteristics independently 
associated with disclosure. To avoid overfitting, we selected a model using forward stepwise 
regression, where, at each step, the order of a variable being included in the model is 
determined by the relative improvement in the model fit if that specific variable is included 
versus whether other variables are included. Interactions were examined on the basis of 
previous literature and a priori hypotheses by including product terms in regression models. 
All analyses were conducted using SAS software Version 9.4 (SAS Institute Inc., Cary, NC) 
and STATA software version 11.2 [26].
RESULTS
Three-hundred and thirty-eight individuals were newly identified as HIV-infected at 
baseline and among those, 336 participants completed the one-month follow-up interview 
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and were eligible for this analysis. One month after receiving HTC, 34.8% of participants (n 
= 117) reported that they had not disclosed to anyone (Table I).
The median number of people that participants disclosed to was 3 (interquartile range 0–11). 
Among those who did not disclose, 24% had shared needles/syringes and 33% were sexually 
active and not using condoms consistently in the previous 3 months suggesting that many of 
those who did not disclose were also engaging in injecting and sexual risk behaviors.
In bivariate analysis, a subscale of social support, positive interactions (POS), higher level 
of HIV knowledge and history of incarceration were significantly associated with disclosure 
1 month after receiving results. In multivariate analysis, a higher score on the POS scale 
(Adjusted OR [AOR]: 1.7; 95% CI: 1.1,2.8), a higher score on the panel of questions to 
assess HIV knowledge (AOR: 1.8; 95% CI: 1.0,3.0) and a history of having been 
incarcerated (AOR: 2.0; 95% CI: 1.2, 3.2) remained significantly associated with disclosure 
(Table IIA).
On qualitative examination of the disclosure rates, a three-way interaction was found. 
Among those who had ever been incarcerated (35%), higher HIV knowledge was associated 
with disclosure (Table IIB(i)), whereas among those who had never been incarcerated, social 
support in the form of positive interactions, was associated with disclosure (Table IIB(ii)).
To understand how social support may play a role in disclosure to family members and 
injecting partners, we assessed the association between social support and disclosure to at 
least one family member and the association between social support and disclosure to at 
least one injecting partner. In bivariate analysis as shown in Table III, higher levels of three 
types of social support (tangible (TAN), emotional/informational (EMI) and positive 
interactions (POS)), and also a history of incarceration were associated with disclosure to a 
family member. Those who reported unprotected sex in the previous 3 months were less 
likely to disclose to a family member.
In multivariate analysis a higher score on the positive interactions subscale of social support 
and a history of incarceration remained statistically significant while unprotected sex 
remained significant with lack of disclosure to a family member. The other two social 
support subscales, EMI and TAN, were no longer significant. For disclosure to an injecting 
partner (Table IV), sharing of injecting solutions in the previous 3 months, a history of being 
in a drug treatment program, knowing someone who is taking ART, believing that ART is 
effective, believing ART is safe, and HIV knowledge were statistically significant in 
bivariate analyses.
In multivariate analysis, a history of being in a drug treatment program, knowing someone 
who is taking ART, and believing that ART is safe were statistically significantly associated 
with disclosure with an injecting partner. Those who had been previously tested for HIV 
were less likely to disclose to an injecting partner.
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In our study, a substantial proportion of HIV-infected PWID (34.8%) did not disclose their 
HIV status to anyone one month after HTC, potentially leaving these individuals without 
emotional, informational and tangible HIV-related support at a time that may be critical both 
for accessing HIV care as well as for reducing HIV risk behaviors to prevent transmission. 
Among participants who disclosed, the vast majority (95%) disclosed to family members, 
including spouses. This finding is consistent with previous research among PWID that found 
that PWID are more likely to disclose to family members [27] and that disclosure is tied to 
social relationships [28]. In Vietnam, a country profoundly influenced by Confucianism, 
family is central to society and a core source of support; therefore family is the first choice 
of disclosure for many. In China, a culture also influenced by Confucianism [1], researchers 
have found that most PLWHAs disclose their HIV status first to a close family member, 
often a spouse or sibling [1], and that family members go on to aid the disclosure process 
[29,30]. In our previous qualitative work, we also found that after disclosure, family 
members tended to provide emotional and tangible support to HIV-infected PWID [19].
In this study, among those without a history of incarceration, social support in the form of 
positive interactions was associated with disclosure. These findings reiterate the importance 
of social support networks in facilitating disclosure and mirror previous research which has 
shown that disclosure is higher when individuals perceive they are likely to receive help 
[31,32] from an existing social support network.
In this study, we found that among PWID with a history of incarceration, those with more 
knowledge about HIV and treatment may be more likely to disclose than those with a lower 
level of knowledge. Incarceration of drug users in Vietnam is relatively common and while 
community members may suspect certain individuals of being a drug user, incarceration is a 
public confirmation of those suspicions. It may be that HIV status is less stigmatizing than 
illegal injection drug use [19] among this sub-group of drug users who have been 
incarcerated, and since they may perceive that their drug use is public and that they have 
“nothing more to lose”, they may be more willing to disclose, particularly if their knowledge 
increases their awareness of treatment options. This may also explain why individuals with a 
history of incarceration were more likely to disclose to family members. Another study on 
HIV disclosure among HIV-infected men who have sex with men found that men who were 
more “out” were more likely to disclose to a sexual partner. Both this study and ours suggest 
that once a stigmatized behavior is public, HIV disclosure may be more likely [33]. This 
finding also confirms other studies showing that lack of correct knowledge about HIV is 
associated with non-disclosure [34].
Disclosure to an injecting partner was associated with beliefs about and exposure to ART as 
well as a history of drug treatment. A history of having been in drug treatment programs 
may operate in the same way as incarceration; those who have been in drug treatment may 
feel their drug use is more public and that with nothing “to lose”, they can only “gain” social 
support through disclosure. In addition to participation in drug treatment programs, knowing 
someone who has taken ART and believing HIV treatments are safe were both associated 
with disclosure to an injecting partner. In order to know that someone is on ART, that 
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person likely disclosed to the participant, perhaps making disclosure more normative. 
Furthermore, knowing ART is a safe and viable option may provide a more positive outlook 
to the future and increase one’s willingness to share information about his status, which in 
turn, could lead to more social support and/or to HIV prevention measures between injecting 
partners.
While disclosure to injecting partners was associated with a greater awareness of ART, 
disclosure to family members was tied to sexual risk. Participants who reported unprotected 
sex in the previous 3 months were less likely to disclose to a family member. Our previous 
study found that inconsistent condom use between PWID and their sexual partners is linked 
to less communication about HIV more generally [35]; this in turn, may lead to a lack of 
immediate communication about HIV positive status to spouses.
Overall, our study found that social support was associated with general disclosure, and 
disclosure to a family member, but was not associated with disclosure to an injecting 
partner. This may be in part because individuals with an existing positive support network 
may have disclosed to family members to enhance their HIV-related social support, such as 
transport to HIV facilities and assistance with the paperwork to initiate ART. On the other 
hand, disclosure to an injecting partner may be related to prevention of HIV transmission, 
and willingness to disclose may be more dependent on the ability to share information 
without risk of additional stigma. The belief that ART was safe and knowing others that had 
disclosed and were on ART may have made both disclosure and HIV itself less stigmatizing.
There were several limitations to this study. First, disclosure was self-reported and 
participants were encouraged at post-test counseling to disclose if appropriate. Therefore, 
there may be social desirability bias that would overestimate disclosure. In addition, we did 
not measure the order or reason for disclosure; it would have been informative to know who 
had been informed first and why in order to further promote disclosure in the future. Finally, 
since our enrollment criteria required participants to be able and willing to bring in an HIV-
negative injecting partner, our study excluded individuals who typically inject alone.
Despite these limitations, our study has important implications for future practice and 
research. HIV disclosure has been associated with benefits in terms of physical and mental 
health [36,37] and engagement in the continuum of HIV care. Among PWID, a highly 
stigmatized population in Vietnam and many countries globally, access to HIV care is 
disproportionately low and interventions to increase access are urgently needed. However, 
the disclosure process is complex and has both benefits and risks to HIV –positive PWID. In 
order to facilitate access to care, future intervention programs should consider both the 
potential benefits and risks associated with HIV disclosure and assist HIV-positive PWID to 
prepare for HIV disclosure and reduce potential negative impacts that come with it. 
Formative research from this study found that HIV stigma may temper the drug-related 
stigma that PWID have already experienced within their families, as they may be perceived 
as “sick” and requiring care-taking by the family, thereby tipping the risk-benefit equation 
towards disclosure [19]. Understanding participants’ background and context (e.g., history 
of incarceration, history of prior HIV testing, quality of social support) may be helpful for 
HTC counselors to tailor their counseling content. HTC counselors should also clearly 
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describe the availability and efficacy of early treatment for HIV. And finally, interventions 
to enhance social support and HIV communication between spouses and sexual partners, 
both prior and after an HIV-diagnosis through small group or couples counseling sessions 
may help provide newly infected PWID with a foundation for disclosure. Further research is 
needed to determine how disclosure changes over time, and if there is a causal association 
between disclosure and HIV risk reduction and access to HIV care in this highly 
marginalized population.
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Table I
Baseline characteristics among HIV-infected participants who did not know their status at baseline
Baseline characteristics Total N Did Not Disclose 




Overall 336 117 (100.0) 219 (100.0)
Age in years
 < 30 years 66 22 (18.8) 44 (20.1) Ref.
 30–34 100 36 (30.8) 64 (29.2) 0.9 (0.5–1.7)
 35–39 92 34 (29.1) 58 (29.5) 0.9 (0.4–1.7)
 40+ 78 25 (21.4) 53 (24.2) 1.1 (0.5–2.1)
Marital status
 Single (never married) 125 45 (38.5) 80 (36.5) Ref.
 Married or Living with partner 163 59 (50.4) 104 (47.5) 1.0 (0.6–1.6)
 Widowed or Divorced 32 8 (6.8) 24 (11.0) 1.7 (0.7–4.1)
 Separated 16 5 (4.3) 11 (5.0) 1.2 (0.4–3.8)
Education level
 Primary or No Schooling 30 10 (8.5) 20 (9.1) Ref.
 Secondary Schooling 193 78 (66.7) 115 (52.5) 0.7 (0.3–1.7)
 High Schooling 95 25 (21.4) 70 (32.0) 1.4 (0.6–3.4)
 University or higher 18 4 (22.2) 14 (6.4) 1.7 (0.5–6.7)
Employment status
 Working full-time (≥30 hours/week) 236 79 (67.5) 157 (71.7) Ref.
 Working part-time (<30 hours/week) 64 24 (20.5) 40 (18.3) 0.8 (0.5–1.5)
 Unemployed or unable to work 36 14 (12.0) 22 (10.0) 0.9 (0.4–1.8)
Any sharing of injecting solutions, past 3 months
 No 83 29 (24.8) 54 (24.7) Ref.
 Yes 253 88 (75.2) 165 (75.3) 1.0 (0.6–1.7)
Any sharing of needle/syringe, past 3 months
 No 249 89 (76.1) 160 (73.1) Ref.
 Yes 87 28 (23.9) 59 (26.9) 1.2 (0.7–2.0)
Ever been in a drug treatment program
 No 241 86 (73.5) 155 (70.8) Ref.
 Yes 95 31 (26.5) 64 (29.2) 1.1 (0.7–1.9)
Any unprotected sex in the past 3 months
 No 242 78 (66.7) 164 (74.9) Ref.
 Yes 94 39 (33.3) 55 (25.1) 0.7 (0.4–1.1)
Have you ever been tested for HIV (i.e., prior to this study)?
 No 268 95 (81.2) 173 (79.0) Ref.













Go et al. Page 12
Baseline characteristics Total N Did Not Disclose 




 Yes 68 22 (18.8) 46 (21.0) 1.1 (0.7–2.0)
Do you know anyone who has taken or is taking ARVs?
 No 220 81 (69.8) 139 (63.5) Ref.
 Yes 115 35 (30.2) 80 (36.5) 1.3 (0.8–2.2)
Which of the following best describes how well you think HIV 
treatments work?
 -None of the treatments work/Don’t know 20 9 (7.7) 11 (5.0) Ref.
 -Treatments can prevent some people from getting sick from 
HIV
316 108 (92.3) 208 (95.0) 1.6 (0.6–3.9)
Which of the following best describes how safe you think HIV 
treatments are?
 -Treatments are not safe/Don’t know 37 15 (12.8) 22 (10.1) Ref.
 -Treatments are very safe/safe with side effects 299 102 (87.2) 197 (89.9) 1.3 (0.7–2.6)
Have you ever been incarcerated?
 No 217 86 (73.5) 131 (59.8) Ref.
 Yes 119 31 (26.5) 88 (40.2) 1.9 (1.1–3.0)*
Social support sub-scale (0–100): EMI median
 0–62 170 66 (56.4) 104 (47.5) Ref.
 63–100 166 51 (43.6) 115 (52.5) 1.4 (0.9–2.2)
Social support sub-scale (0–100): TAN median
 0–93 214 82 (70.1) 132 (60.3) Ref.
 94–100 122 35 (29.9) 87 (39.7) 1.5 (0.9–2.5)
Social support sub-scale (0–100): POS median
 0–56 173 71 (60.7) 102 (46.6) Ref.
 57–100 163 46 (39.3) 117 (53.4) 1.8 (1.1–2.8)*
Social support sub-scale (0–100): AFF median
 0–74 167 63 (53.9) 104 (47.5) Ref.
 75–100 169 54 (46.1) 115 (52.5) 1.3 (0.8–2.0)
HIV stigma score (quartiles)
 1st 63 20 (17.1) 43 (19.6) Ref.
 2nd 107 41 (35.0) 66 (30.1) 0.7 (0.4–1.4)
 3rd 77 25 (21.4) 52 (23.8) 1.0 (0.5–2.0)
 4th 89 31 (26.5) 58 (26.5) 0.9 (0.4–1.7)
IDU stigma score (quartiles)
 1st 99 33 (28.2) 66 (30.1) Ref.
 2nd 77 27 (23.1) 50 (22.8) 0.9 (0.5–1.7)
 3rd 47 12 (10.3) 35 (16.0) 1.5 (0.7–3.2)
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Baseline characteristics Total N Did Not Disclose 




 4th 113 45 (38.5) 68 (31.1) 0.8 (0.4–1.3)
Total number in your social network
 0–2 persons 154 56 (47.9) 98 (44.7) Ref.
 3 76 27 (23.1) 49 (22.4) 1.0 (0.6–1.8)
 4 47 15 (12.8) 32 (14.6) 1.2 (0.6–2.4)
 5+ 59 19 (16.2) 40 (18.3) 1.2 (0.6–2.3)
HIV knowledge score: Number of questions answered correctly, 
out of 7 questions total
 0–6 78 35 (29.9) 43 (19.6) Ref.
 7 258 82 (70.1) 176 (80.4) 1.7 (1.0–2.9)*
CD4 count at baseline: Quartiles
 0–126 82 32 (28.6) 50 (23.0) Ref.
 127–242 82 24 (21.4) 58 (26.7) 1.5 (0.8–3.0)
 243–377 82 25 (22.3) 57 (26.3) 1.5 (0.8–2.8)
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Table IIA
Analysis of HIV disclosure to at least one person
Baseline characteristics Total N Bivariate OR (95% CI) Multivariate OR (95% CI)
Overall 336
Have you ever been incarcerated?
 No 217 Ref. Ref.
 Yes 119 1.9 (1.1–3.0)* 2.0 (1.2–3.2)**
HIV knowledge score: Number of questions answered correctly, out of 
7 questions total
 0–6 78 Ref. Ref.
 7 258 1.7 (1.0–2.9)* 1.8 (1.0–3.0)*
Social support sub-scale (0–100): POS median
 0–56 173 Ref. Ref.
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Table IIB
% HIV Disclosure to at least one person:
i. among participants who were EVER INCARCERATED at baseline
ii. among participants who were NEVER INCARCERATED at baseline
The shaded vs. unshaded discrimination is the simplest one within levels of incarceration that describes approximately the distinction between high 
(>70) % disclosure rate versus moderate or lower rate (exceptions are in parentheses).
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Table III
Disclosure of HIV status to at least one family member
Baseline characteristics Total N Bivariate OR (95% CI) Multivariate OR (95% CI)
Overall 336
Have you ever been incarcerated?
 No 217 Ref. Ref.
 Yes 119 1.8 (1.1–2.9)* 1.9 (1.2–3.2)**
Any unprotected sex in the past 3 months
 No 242 Ref. Ref.
 Yes 94 0.6 (0.4–0.98)* 0.5 (0.3–0.8)*
Social support sub-scale (0–100): POS dichotomized at median
 0–56 173 Ref. Ref.
 57–100 163 2.0 (1.2–3.1)** 2.2 (1.4–3.6)**
Social support sub-scale (0–100): EMI median
 0–62 170 Ref. ---
 63–100 166 1.7 (1.1–2.6)*
Social support sub-scale (0–100): TAN median
 0–93 214 Ref. ---
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Table IV
Disclosure of HIV status to at least one injecting partner
Baseline characteristics Total N Bivariate OR (95% CI) Multivariate OR 
(95% CI)
Overall 336
Any sharing of injecting solutions, past 3 months
 No 83 Ref. ---
 Yes 253 1.9 (1.1–3.2)*
Have you ever been in a drug treatment program?
 No 241 Ref. Ref.
 Yes 95 1.7 (1.0–2.7)* 2.0 (1.2–3.3)*
Have you ever been tested for HIV (i.e., prior to this study)?
 No 268 Ref. Ref.
 Yes 68 0.7 (0.4–1.2) 0.5 (0.3–0.9)*
Do you know anyone who has taken or is taking ARVs?
 No 220 Ref. Ref.
 Yes 115 2.1 (1.3–3.4)** 2.2 (1.4–3.6)**
Which of the following best describes how well you think HIV treatments 
work?
 -None of the treatments work/Don’t know 20 Ref. ---
 -Treatments can prevent some people from getting sick from HIV 316 3.3 (0.9–11.4)*
Which of the following best describes how safe you think HIV treatments 
are?
 Treatments are not safe or Don’t know 37 Ref. Ref.
 Treatments are safe 299 3.9 (1.5–10.4)** 3.8 (1.4–10.2)**
HIV knowledge score: Number of questions answered correctly, out of 7 
questions total
 0–6 78 Ref. ---
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